Shenzhen, China-based VivoLight Medical (Chinese: 深圳市中科微光医疗器械技术有限公司) has received investments of over 100 million yuan ($14 million) from several strategic investors, including SinoWisdom Investment (Chinese: 华睿投资) and Guangzhou Industrial Investment Capital (Chinese: 广州产投资本), for the development of new medical laser products, clinical registration, and overseas market expansion.

Founded in 2012, VivoLight is incubated and supported by the Xi’an Institute of Optics and Precision Mechanics of the Chinese Academy of Sciences (Chinese: 中国科学院西安光机所) and is committed to the independent development, global innovation and independent manufacturing of medical devices for minimally invasive interventional diagnosis and treatment using laser technology.

In April 2020, VivoLight received approval from China’s National Medical Products Administration (NMPA) for its proprietary Optical Coherence Tomography (OCT) system. In December 2021, the company received NMPA approval for its innovative multimodality OCT system which is the first multimodality OCT system in the field of coronary OCT for clinical use.

We are very grateful to our investors for their recognition and support of our company. The post-epidemic era brings more opportunities for companies with innovative awareness and ability and modern business thinking. VivoLight Medical is about to launch a major innovative product in addition to deepening its existing coronary OCT product, and the financing funds will be used to accelerate technology development and product promotion,” said Mr Rui Zhu (朱锐), Founder of VivoLight Medical.

en_GBEnglish (UK)